Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2022-02-02 Director's Dealing
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-02-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-02-02 English
SC 13D/A
Major Shareholding Notification
2022-02-01 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 10, 2022, for Cognition Therapeutics, Inc. It includes a Regulation FD Disclosure and an attached Exhibit 99.1 described as an "Investor presentation." The text explicitly states that the presentation is furnished for Regulation FD purposes and is not considered "filed" under the Exchange Act. The document does not contain financial statements or detailed financial analysis but rather a presentation intended for investors. The length is 3881 characters, which is relatively short and consistent with an announcement or furnishing of a presentation rather than a full report. Therefore, this document is best classified as an Investor Presentation (IP).
2022-01-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 18, 2021, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2021. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, indicating this is a current report announcing earnings results rather than the earnings release itself. The document length is 3935 characters, which is relatively short and consistent with an announcement rather than a full earnings release. Therefore, this document is best classified as an Earnings Release announcement (ER).
2021-11-18 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-17 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.